At the time of writing, Bolt Biotherapeutics Inc [BOLT] stock is trading at $0.73, up 2.41%. An important factor to consider is whether the stock is rising or falling in short-term value. The BOLT shares have lost -0.42% over the last week, with a monthly amount drifted -1.07%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bolt Biotherapeutics Inc [NASDAQ: BOLT] stock has seen the most recent analyst activity on January 06, 2022, when Morgan Stanley downgraded its rating to a Equal-Weight. Previously, SVB Leerink started tracking the stock with Outperform rating on March 02, 2021, and set its price target to $36. On March 02, 2021, Stifel initiated with a Buy rating and assigned a price target of $40 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $45 on March 02, 2021. Guggenheim initiated its recommendation with a Buy and recommended $42 as its price target on March 02, 2021.
For the past year, the stock price of Bolt Biotherapeutics Inc fluctuated between $0.65 and $1.56. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Bolt Biotherapeutics Inc [NASDAQ: BOLT] shares were valued at $0.73 at the most recent close of the market. An investor can expect a potential return of 36.99% based on the average BOLT price forecast.
Analyzing the BOLT fundamentals
According to Bolt Biotherapeutics Inc [NASDAQ:BOLT], the company’s sales were 11.32M for trailing twelve months, which represents an 188.83% jump. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -6.61%, Pretax Profit Margin comes in at -5.57%, and Net Profit Margin reading is -5.57%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.52 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7088 points at the first support level, and at 0.6906 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7426, and for the 2nd resistance point, it is at 0.7582.
Ratios To Look Out For
It is important to note that Bolt Biotherapeutics Inc [NASDAQ:BOLT] has a current ratio of 5.68. On the other hand, the Quick Ratio is 5.68, and the Cash Ratio is 0.25. Considering the valuation of this stock, the price to sales ratio is 2.45, the price to book ratio is 0.27.
Transactions by insiders
Recent insider trading involved Quinn William P., Chief Financial Officer, that happened on Dec 12 ’23 when 7500.0 shares were purchased. Chief Financial Officer, Quinn William P. completed a deal on Dec 06 ’23 to buy 2500.0 shares. Meanwhile, Director ENGLEMAN EDGAR sold 0.12 million shares on Nov 30 ’23.
